Details for New Drug Application (NDA): 021268
✉ Email this page to a colleague
The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.
Summary for 021268
Tradename: | TEVETEN HCT |
Applicant: | Abbvie |
Ingredient: | eprosartan mesylate; hydrochlorothiazide |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 600MG;12.5MG | ||||
Approval Date: | Nov 1, 2001 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 600MG;25MG | ||||
Approval Date: | Nov 1, 2001 | TE: | RLD: | No |
Expired US Patents for NDA 021268
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription